Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||ERBB2 G778_S779insCPG|
|Gene Variant Detail|
|Relevant Treatment Approaches||HER inhibitor (Pan) HER2 Inhibitor|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 G778_S779insCPG||lung adenocarcinoma||no benefit||Ado-trastuzumab emtansine||Case Reports/Case Series||Actionable||In a Phase II trial, treatment with Kadcyla (trastuzumab emtansine) resulted in best overall responses of partial response in 44% (8/18) and stable disease in 39% (7/18), and median progression-free survival of 5 months in patients with lung adenocarcinoma harboring ERBB2 (HER2) activating mutations, but one patient specifically harboring a G778_S779insCPG mutation did not have a partial response (PMID: 29989854; NCT02675829).||29989854|
|ERBB2 G778_S779insCPG||Advanced Solid Tumor||sensitive||HER inhibitor (Pan)||Dacomitinib||Preclinical - Cell culture||Actionable||In a preclinical study, Vizimpro (dacomitinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G778_S779insCPG in culture (PMID: 28363995).||28363995|